Susquehanna Fundamental Investments LLC Acquires 54,762 Shares of Nuvation Bio Inc. (NYSE:NUVB)

Susquehanna Fundamental Investments LLC lifted its holdings in Nuvation Bio Inc. (NYSE:NUVB) by 252.0% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 76,494 shares of the company’s stock after purchasing an additional 54,762 shares during the quarter. Susquehanna Fundamental Investments LLC’s holdings in Nuvation Bio were worth $223,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Octagon Capital Advisors LP purchased a new position in Nuvation Bio in the 4th quarter worth about $1,510,000. Pinnacle Wealth Planning Services Inc. bought a new stake in shares of Nuvation Bio in the first quarter worth approximately $105,000. Vanguard Group Inc. grew its stake in shares of Nuvation Bio by 3.0% in the first quarter. Vanguard Group Inc. now owns 7,534,148 shares of the company’s stock worth $27,424,000 after acquiring an additional 219,533 shares during the period. Acadian Asset Management LLC raised its holdings in shares of Nuvation Bio by 81.9% during the first quarter. Acadian Asset Management LLC now owns 1,174,464 shares of the company’s stock valued at $4,273,000 after purchasing an additional 528,660 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD lifted its position in Nuvation Bio by 551.8% during the first quarter. Price T Rowe Associates Inc. MD now owns 1,354,632 shares of the company’s stock valued at $4,932,000 after purchasing an additional 1,146,794 shares during the period. 61.67% of the stock is owned by institutional investors.

Nuvation Bio Trading Up 2.8 %

NUVB opened at $2.41 on Friday. The firm’s 50 day simple moving average is $2.93 and its two-hundred day simple moving average is $3.01. The company has a market capitalization of $594.45 million, a PE ratio of -7.76 and a beta of 1.36. Nuvation Bio Inc. has a 1-year low of $0.95 and a 1-year high of $4.16.

Nuvation Bio (NYSE:NUVB) last announced its earnings results on Monday, August 5th. The company reported ($0.15) EPS for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.09). The company had revenue of $1.44 million during the quarter. Equities analysts forecast that Nuvation Bio Inc. will post -0.4 earnings per share for the current fiscal year.

Analyst Ratings Changes

NUVB has been the subject of a number of research analyst reports. HC Wainwright cut their target price on shares of Nuvation Bio from $8.00 to $7.00 and set a “buy” rating for the company in a research report on Monday, September 16th. Wedbush reaffirmed an “outperform” rating and issued a $5.00 price objective on shares of Nuvation Bio in a report on Wednesday, September 11th. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $5.00 target price on shares of Nuvation Bio in a report on Tuesday, August 6th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Nuvation Bio currently has a consensus rating of “Buy” and a consensus target price of $6.40.

About Nuvation Bio

Nuvation Bio Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer.